We exist to create an alternate future for people with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory for people living with these debilitating diseases.
First-in-class therapies to treat neurodegenerative disease
Alterity is developing first-in-class therapies to treat neurodegenerative disease. Our lead drug candidate, PBT434, has demonstrated efficacy in several animal models of Parkinsonian disorders and is being evaluated in clinical trials.
Alterity Therapeutics Announces Successful Completion of Phase 1 Clinical Trial
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) today announced that it has successfully compleRead More
Alterity Therapeutics talks to Finance News Network
Alterity Therapeutics Limited (ASX:ATH) CEO & Chairman, Geoffrey Kempler, discusses the company’s development pipeline and lead drugRead More
Alterity Therapeutics’ Finance News Network Presentation
On June 6 2019, Alterity Therapeutics Limited (ASX:ATH) CEO & Chairman, Geoffrey Kempler, participated in the Finance News Network InvRead More